Quantitative fetal fibronectin for prediction of preterm birth in asymptomatic twin pregnancy.

Acta Obstet Gynecol Scand

Department of Women and Children's Health, King's College London, St Thomas's Hospital, London, UK.

Published: September 2020

Introduction: To evaluate cervicovaginal fluid quantitative fetal fibronectin, measured by a bedside analyzer, to predict spontaneous preterm birth in twin pregnancy before 30 weeks of gestation.

Material And Methods: In a prospective cohort study, we studied the accuracy of quantitative fetal fibronectin measured between 18 and 27 weeks of gestation in high-risk asymptomatic women with twin pregnancies, to predict spontaneous preterm birth before 30 weeks of gestation. Predefined fetal fibronectin thresholds were ≥10, ≥50 and ≥200 ng/mL. Predictive statistics were also calculated to evaluate accuracy of "early" tests, performed between 18 and 21 weeks and "standard" tests performed between 22 and 27 weeks of gestation in the same cohort. Subgroup analysis was performed according to cervical length measurement. In addition, we compared accuracy of prediction with quantitative fetal fibronectin measured during the standard test period in asymptomatic twin pregnancy with no additional risk factors, to twin pregnancies with one or more additional risk factors for spontaneous preterm birth.

Results: Of 130 eligible women identified with quantitative fetal fibronectin tests undertaken during the standard testing period, 9% delivered before 30 weeks of gestation. Quantitative fetal fibronectin was significantly related to outcome before 30/40 (ROC curves of 0.8 [95% CI 0.7-1]). Early tests were not significantly predictive; ROC area 0.53 (95% CI 0.29-0.81). There was a trend towards better predictive accuracy when one or more additional risk factors for spontaneous preterm birth or cervical length were considered.

Conclusions: Quantitative fetal fibronectin measured from 22 to 27 weeks of gestation accurately predicts spontaneous preterm birth at <30 weeks of gestation. Tests undertaken earlier are of limited value. Consideration of cervical length or prior history in addition to quantitative fetal fibronectin strengthens prediction.

Download full-text PDF

Source
http://dx.doi.org/10.1111/aogs.13861DOI Listing

Publication Analysis

Top Keywords

fetal fibronectin
32
quantitative fetal
28
preterm birth
20
spontaneous preterm
20
weeks gestation
20
fibronectin measured
16
twin pregnancy
12
additional risk
12
risk factors
12
fibronectin
8

Similar Publications

Preeclampsia (PE) is a gestational complication affecting 5% to 10% of all pregnancies. PE is characterized by hypertension and endothelial dysfunction, whose etiology involves, among other factors, alterations in the extracellular matrix (ECM) that can compromise vascular remodeling and trophoblast invasion, ie, processes essential for placental development. Endothelial dysfunction is caused by release of antiangiogenic factors, mainly a soluble fms-like tyrosine kinase-1 (sFlt-1), which antagonizes two endothelial angiogenic factors, the vascular endothelial growth factor (VEGF) and placental growth factor (PLGF).

View Article and Find Full Text PDF
Article Synopsis
  • Preeclampsia is a condition with serious risks for mothers and babies, and new angiogenic markers are being used to help diagnose it quickly in clinical settings.
  • The study analyzed the effectiveness of various point-of-care tests for predicting preeclampsia, focusing on their sensitivity and specificity based on data from 17 relevant studies.
  • Glycosylated fibronectin testing showed promising results with a sensitivity of 0.80 and specificity of 0.84, indicating it could be a valuable tool for clinical decisions regarding preeclampsia in high-risk patients.
View Article and Find Full Text PDF

Objectives: To evaluate glycosylated fibronectin (GlyFn) as a novel biomarker for preeclampsia and preeclampsia-related complications, and to compare GlyFn to traditional biomarkers, including soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF).

Study Design: Secondary analysis of a prospective cohort study (n = 524) with suspected preeclampsia (control), gestational hypertension (GH), or confirmed preeclampsia/hemolysis, elevated liver enzymes and low platelets syndrome (PE/HELLP).

Main Outcome Measures: GlyFn levels in PE/HELLP versus control and GH.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!